Acadia Pharmaceuticals Inc. (ACAD) has been the model of inconsistency and unpredictability over the last year. ACAD is currently trading right in the middle of its 52-week range, between $16.64 and $51.99. It has risen 14% over the last …
The EVP AND GC now owns $2,134,680 of the stock according to the SEC filing. Glenn Baity, EVP AND GC reported the sale of 1,903 shares of ACAD stock. The shares were purchased at an average price of $30.00. Baity now owns …
Acadia Pharmaceuticals wasn't off to the best of days in today's trading session. When the market opened, the stock was trading well into the red. While it made a push for the green, when it broke through the breakeven point, the stock
Six equities research analysts have rated the stock with a hold rating and nine have assigned ... story can be viewed at https://www.thecerbatgem.com/2017/04/26/acadia-pharmaceuticals-inc-acad-shares-sold-by-columbus-circle …
Investors in Acadia Pharmaceuticals Inc (NASD: ACAD) saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the …
On Thursday, June 22nd, Glenn Baity sold 1,903 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $57,090.00. Shares of ACADIA Pharmaceuticals Inc. (ACAD) opened at …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACAD at https://www.zacks.com/ap/ACAD
CNBC12d
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been given an average recommendation of “Hold” by the eighteen analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the …
The stock has a 50 day moving average of $33.70 and a 200-day moving average of $31.73. The Higher end of the revenue forecast is $24.6 Million, while the Lower end of the forecast is $16.4 Million. Pharmaceuticals (NASDAQ:ACAD) last …